IndustryCompany release

Maravai lifts 2026 guidance after Q3 revenue rises 10% on mRNA demand

🇺🇸 Maravai Lifesciences Holdings, Inc. (MRVI) · Wed 04 Nov 2026

The US life-sciences supplier reported third-quarter revenue of $45.9 million, with TriLink mRNA products up 28%, and raised its full-year revenue and Adjusted EBITDA outlook.

Maravai LifeSciences reported third-quarter 2026 results on 4 November, with revenue of $45.9 million, up 10.1% on the same period a year earlier. The company recorded a net loss of $24.0 million for the quarter and Adjusted EBITDA of $5.8 million.

Revenue at TriLink, Maravai's nucleic acid production business, rose 11.8%. Within that segment, mRNA products grew 28%. Cygnus, the company's other reported business, posted revenue growth of 7.5%.

Following the quarter, Maravai raised its 2026 guidance. It now expects revenue of $212-216 million and Adjusted EBITDA of $40-42 million. The summary available does not state the previous guidance ranges, nor does it detail the drivers behind the net loss.

The full release was not available for this report, so segment revenue figures, customer mix and any commentary from management are not covered here.

What it means for your team

  • Sustained 28% growth in TriLink mRNA products points to continued demand for mRNA materials, relevant to teams planning supply of critical raw materials and components.
  • Suppliers of nucleic acid and related reagents remain a key link in mRNA development chains, so quality teams may wish to keep supplier qualification and continuity plans current.
  • The raised guidance is a company projection, not a guarantee; teams should rely on supplier audits and agreements rather than financial outlooks when assessing supply risk.

Company's press release (SEC filing): Maravai Lifesciences Holdings, Inc. ↗

Article written by VigiEye from the official source (Maravai Lifesciences Holdings, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →